Atrium Therapeutics grants RSUs and options to executive
Atrium Therapeutics, Inc. granted equity awards to executive Stephanie Kenney on April 20, 2026.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Atrium Therapeutics, Inc. granted equity awards to executive Stephanie Kenney on April 20, 2026. She received 30,000 shares of common stock as restricted stock units, bringing her direct common stock holdings to 35,460 shares after the award.
Kenney was also granted stock options for 60,000 shares of common stock at an exercise price of $14.30 per share, expiring on April 20, 2036. Both the RSUs and options vest over multiple years starting March 20, 2027, subject to her continued service with the company.
Insider Trade Summary
Grant/Award: 90,000 shares
Grant/Award
2 txns
Insider
Kenney Stephanie
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 60,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 30,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 60,000 contracts (Direct);
Common Stock — 35,460 shares (Direct)
Footnotes (2)
- F1. Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
- F2. Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
Key Figures
RSU grant: 30,000 shares
Common shares after award: 35,460 shares
Stock option grant: 60,000 options
+4 more
7 metrics
RSU grant
30,000 shares
Restricted stock units awarded April 20, 2026
Common shares after award
35,460 shares
Direct common stock holdings after RSU grant
Stock option grant
60,000 options
Options on common stock awarded April 20, 2026
Option exercise price
$14.30 per share
Strike price for 60,000 stock options
Option expiration
April 20, 2036
Expiration date of granted stock options
RSU initial vesting
25% on March 20, 2027
First vesting tranche of 30,000 RSUs
Option initial vesting
25% on March 20, 2027
First vesting tranche of 60,000 options
Key Terms
restricted stock units ("RSUs"), Stock Option (Right to Buy), vest, exercisable, +1 more
5 terms
restricted stock units ("RSUs") financial
"Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)... underlying security title Common Stock, underlying security shares 60000.0000"
vest financial
"Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027..."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercisable financial
"shares underlying this option shall vest and become exercisable on March 20, 2027..."
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer on each such vesting date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Atrium Therapeutics (RNA) report for Stephanie Kenney?
Atrium Therapeutics reported that executive Stephanie Kenney received equity awards, including 30,000 restricted stock units and 60,000 stock options. These compensation-related grants increase her equity stake without any open-market buying or selling activity disclosed in this filing.
What equity awards did Atrium Therapeutics (RNA) grant to Stephanie Kenney?
Atrium Therapeutics granted Kenney 30,000 restricted stock units and stock options covering 60,000 shares of common stock at a $14.30 exercise price. These awards form part of her long-term equity compensation package with the company.
When do Stephanie Kenney’s Atrium Therapeutics (RNA) RSUs vest?
Twenty-five percent of Kenney’s 30,000 restricted stock units vest on March 20, 2027. The remaining RSUs vest in three substantially equal yearly installments thereafter, contingent on her continued service with Atrium Therapeutics on each vesting date.
What are the vesting terms of Stephanie Kenney’s Atrium Therapeutics (RNA) stock options?
For Kenney’s 60,000 stock options, 25% of the underlying shares vest and become exercisable on March 20, 2027. The remaining shares vest in 36 substantially equal monthly installments, assuming she continues to serve Atrium Therapeutics on each vesting date.
What is the exercise price and expiration date of Stephanie Kenney’s Atrium Therapeutics (RNA) options?
Kenney’s stock options have an exercise price of $14.30 per share and expire on April 20, 2036. She can only exercise vested portions of these options according to the multi-year vesting schedule tied to her continued service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
